Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $409.34 | 7 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $115.87 | 2 | $0 (2024) |
| Amgen Inc. | $102.52 | 1 | $0 (2023) |
| Incyte Corporation | $83.72 | 1 | $0 (2022) |
| PFIZER INC. | $82.30 | 2 | $0 (2022) |
| Aroa Biosurgery Incorporated | $24.93 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.19 | 1 | ABBVIE INC. ($17.19) |
| 2023 | $127.45 | 2 | Amgen Inc. ($102.52) |
| 2022 | $98.02 | 2 | Incyte Corporation ($83.72) |
| 2017 | $166.68 | 2 | AbbVie, Inc. ($98.68) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: IMMUNOLOGY | ||||||
| 11/02/2023 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $102.52 | General |
| Category: Inflammation | ||||||
| 09/08/2023 | Aroa Biosurgery Incorporated | — | Food and Beverage | Cash or cash equivalent | $24.93 | General |
| 05/05/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $83.72 | General |
| Category: Dermatology | ||||||
| 04/27/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: DERMATOLOGY | ||||||
| 11/01/2017 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $68.00 | General |
| Category: DERMATOLOGY | ||||||
| 04/12/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $98.68 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 2,179 | 4,105 | $518,208 | $169,141 |
| 2022 | 16 | 2,274 | 4,120 | $518,358 | $164,939 |
| 2021 | 20 | 2,483 | 4,602 | $552,726 | $195,573 |
| 2020 | 19 | 2,429 | 4,507 | $539,113 | $190,411 |
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 389 | 489 | $120,294 | $32,358 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 235 | 257 | $61,680 | $20,942 | 34.0% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 117 | 162 | $53,298 | $19,857 | 37.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 296 | 341 | $56,265 | $19,790 | 35.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 342 | 445 | $60,075 | $15,374 | 25.6% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 193 | 338 | $32,448 | $13,233 | 40.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 94 | 113 | $27,233 | $9,425 | 34.6% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 24 | 29 | $18,270 | $8,880 | 48.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 279 | 1,693 | $22,009 | $8,370 | 38.0% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 40 | 54 | $19,602 | $6,297 | 32.1% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 24 | 29 | $15,805 | $6,022 | 38.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 59 | 59 | $13,275 | $4,006 | 30.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 74 | 80 | $7,986 | $2,810 | 35.2% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 13 | 16 | $9,968 | $1,777 | 17.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 434 | 519 | $127,674 | $33,939 | 26.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 340 | 385 | $63,201 | $20,729 | 32.8% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 113 | 144 | $47,376 | $17,404 | 36.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 358 | 457 | $61,695 | $15,243 | 24.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 205 | 362 | $34,752 | $14,454 | 41.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 165 | 174 | $41,760 | $14,012 | 33.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 276 | 1,664 | $21,632 | $8,149 | 37.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 89 | 107 | $25,787 | $8,143 | 31.6% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2022 | 18 | 20 | $17,400 | $6,927 | 39.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 98 | 98 | $22,050 | $6,436 | 29.2% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2022 | 17 | 17 | $10,710 | $5,277 | 49.3% |
About Dr. Charlotte Kutsch, MD
Dr. Charlotte Kutsch, MD is a Dermatology healthcare provider based in Missoula, Montana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295815397.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charlotte Kutsch, MD has received a total of $409.34 in payments from pharmaceutical and medical device companies, with $17.19 received in 2024. These payments were reported across 7 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($409.34).
As a Medicare-enrolled provider, Kutsch has provided services to 9,365 Medicare beneficiaries, totaling 17,334 services with total Medicare billing of $720,064. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Missoula, MT
- Active Since 10/16/2006
- Last Updated 12/14/2016
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1295815397
Products in Payments
- Otezla (Drug) $102.52
- OPZELURA (Drug) $83.72
- EUCRISA (Drug) $82.30
- SKYRIZI (Biological) $17.19
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Missoula
Shannon Foster, M.d, M.D
Dermatology — Payments: $11,217
Troy Davis, Pa-C, PA-C
Dermatology — Payments: $5,646
Jessica Sempler, M.d, M.D
Dermatology — Payments: $5,358
Andrew Tegeder, Md, MD
Dermatology — Payments: $3,539
Erika Hagstrom, Md, MD
Dermatology — Payments: $1,643
Jacob Inda, Md, MD
Dermatology — Payments: $1,488